Molecular Medicine Tri-Conference 2010
- 15 Downloads
Cambridge Healthtech Institute’s 17th International Molecular Medicine Tri-Conference convened February 3–5, 2010, at San Francisco’s Moscone North Convention Center, welcoming over 2700 attendees from 38 countries. Along with regular delegates, the 1223 participating companies, 130 exhibitors, and 44 sponsors engaged in the recurring Tri-Conference theme of ‘Shaping Future Medicine.’
The conference again had a strong focus on personalized medicine, in all its multiple forms. Keynote speaker John Crowley, CEO of Amicus Therapeutics, Inc., captivated the audience with his truly personal story of social entrepreneur-ship in drug research, inspired by the 1998 diagnosis of glycogen storage disease type II (Pompe disease) — a rare and often fatal genetic neuromuscular disorder — in two of his infant children. Historically, drug companies have lacked the financial incentive to develop treatments for such orphan diseases. So Crowley, driven by motivation to help his...
KeywordsBreast Cancer Trastuzumab Personalized Medicine Glycogen Storage Disease Translational Medicine
- 4.US FDA. Mammaprint 510k summary [online]. Available from URL: http://www.accessdata.fda.gov/cdrh_docs/pdf8/K081092.pdf [Accessed 2010 Mar 17]
- 5.European Organization for Research and Treatment of Cancer. Genetic testing or clinical assessment in determining the need for chemotherapy in women with breast cancer that involves no more than 3 lymph nodes (MINDACT) [Clinical-Trials.gov identifier NCT00433589]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00433589?term=mindact&rank=1 [Accessed 2010 Mar 17]